SAB Biotherapeutics (SABS)
(Delayed Data from NSDQ)
$2.23 USD
+0.04 (1.83%)
Updated Aug 7, 2025 04:00 PM ET
After-Market: $2.20 -0.03 (-1.35%) 6:56 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
SAB Biotherapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
SABS 2.23 +0.04(1.83%)
Will SABS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for SABS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SABS
SAB Biotherapeutics, Inc. (SABS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Oculis Holding AG (OCS) Reports Q1 Loss, Tops Revenue Estimates
SABS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcutis Biotherapeutics, Inc. (ARQT) Reports Q1 Loss, Tops Revenue Estimates
Other News for SABS
SAB BIO Reports Second Quarter Financial Results and Highlights Company Updates | SABS Stock News
SAB Biotherapeutics reports Q2 EPS ($1.09) vs. (79c) last year
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
SAB Biotherapeutics (SABS) Stock Rating Maintained as Price Target Adjusted | SABS Stock News